Efficacy and safety of saroglitazar for the management of dyslipidemia: A systematic review and meta-analysis of interventional studies.

Manik ChhabraKota VidyasagarSai Krishna GudiJatin SharmaRishabh SharmaMuhammed Rashid

Published in: PloS one (2022)

Saroglitazar appeared to be an effective and safer therapeutic option for improving dyslipidemia in patients. However, comparative studies of saroglitazar with the other pharmacological agents are warranted.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
patient reported outcomes